Anavex Life Sciences Corp. (AVXL)

3.8500 +0.0900 (+2.39%) 收市：04:00PM EDT

Anavex Life Sciences Corp.

630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939
https://www.anavex.com

版塊: Healthcare
行業: Biotechnology
全職員工: 40

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.	President, CEO, Secretary & Director	828.25k	3.2M	1966
Ms. Sandra Boenisch CPA, CGA	Principal Financial Officer & Treasurer	194.36k	無	1981
Mr. Stephan Toutain M.B.A., M.S.	Senior VP of Operations & COO	無	無	1966
Dr. Walter E. Kaufmann M.D.	Chief Scientific Officer	無	無	無
Clint Tomlinson	VP of Corporate	無	無	無
Dr. Adebayo Laniyonu Ph.D.	Senior Vice President of Nonclinical Development	無	無	無
Dr. Edward R Hammond M.D., M.P.H., Ph.D.	Chief Medical Officer	無	無	無
Dr. Kun Jin Ph.D.	Head of Biostatistics	無	無	無
Mr. David Goldberger R.Ph.	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

公司管治

截至 2024年5月1日 止，Anavex Life Sciences Corp. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：7；董事會：3；股東權利：1；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。